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We aimed at performing a calibration and re-calibration process using six standard risk factors from 
Northern (NE, N = 2360) or Southern European (SE, N = 2789) middle-aged men of the Seven Countries 
Study, whose parameters and data were fully known, to establish whether re-calibration gave the 
right answer. Greenwood-Nam-D’Agostino technique as modified by Demler (GNDD) in 2015 produced 
chi-squared statistics using 10 deciles of observed/expected CHD mortality risk, corresponding to 
Hosmer-Lemeshaw chi-squared employed for multiple logistic equations whereby binary data are used. 
Instead of the number of events, the GNDD test uses survival probabilities of observed and predicted 
events. The exercise applied, in five different ways, the parameters of the NE-predictive model to SE 
(and vice-versa) and compared the outcome of the simulated re-calibration with the real data. Good 
re-calibration could be obtained only when risk factor coefficients were substituted, being similar in 
magnitude and not significantly different between NE-SE. In all other ways, a good re-calibration could 
not be obtained. This is enough to praise for an overall need of re-evaluation of most investigations 
that, without GNDD or another proper technique for statistically assessing the potential differences, 
concluded that re-calibration is a fair method and might therefore be used, with no specific caution.
Re-calibration is the statistical process which allows to adapt a risk function applied to a different population in 
view of eliminating the over- or under-estimation of risk in the importing population1,2. This has become a com-
mon practice in cardiovascular risk estimation when some research groups, such as the Euro-Score group and 
the Framingham research group, have applied their risk functions to other countries or populations. Calibration 
describes how accurately estimates of prediction of survival (or mortality or incidence) from a model reflect the 
survival (or mortality or incidence) in the observed data. Therefore, it is an index of accuracy. A well calibrated 
risk score or prediction rule assigns correct event probabilities at all levels of predicted risk. A miss-calibrated 
process under- or over-predicts the event probabilities, sometimes globally (calibration at large), sometimes 
depending on risk levels of specific covariates.
The reason for using re-calibration procedures is that in some countries there are no valuable population stud-
ies to produce local risk functions. On the other hand, this acknowledges the fact that applying risk functions of 
the derivation population may produce gross over- or under-estimation of risk in the validation population. This 
fact was first demonstrated many years ago3, and re-documented more recently4, by the Seven Countries Study of 
Cardiovascular Diseases, where risk functions for coronary heart disease (CHD) incidence or mortality derived 
from Northern European (NE) or North American populations grossly over-estimated the risk when applied to 
Southern European (SE) populations, and vice-versa. This problem was basically ignored by those who proposed 
the so called European coronary risk chart in 19945 using the Framingham Heart Study predictive models, that 
have repeatedly been shown to over-estimate coronary risk in Europe6–9. It also became the reason why, years 
later, the Euro-Score research group was eventually compelled to produce two different charts for CHD mortality 
prediction in Europe, corresponding to high risk and low risk populations respectively10. On the other hand, a 
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number of contributions were published in the last 15 years11–23 that, in the majority, claimed successful usually 
starting from the assumption that the “imported” coefficients should be valid for the validation population.
The purpose of this analysis was to perform a calibration and re-calibration process using data from two pop-
ulation groups whose parameters and data were all fully known, so that we could establish whether re-calibration 
gave the right answer. Moreover, we took advantage by the use of a recently proposed technique for assessing 
statistically calibration outcome that was specifically designed and tested for material consisting of survival data24.
Material and Methods
Population samples used for this analysis derived from the Seven Countries Study of Cardiovascular Diseases. 
We selected two rural sample in Finland (East and West Finland) and one in the city of Zutphen, the Netherlands 
that were pooled together to represent Northern Europe (NE). Then, we selected two rural samples in Italy 
(Crevalcore and Montegiorgio) and two rural samples in Greece (Crete and Corfu) that were pooled together to 
represent Southern Europe (SE). The entry examination was held between 1959 and 1961 with the enrolment of 
2555 middle-aged men in NE and 2927 men in SE, representing respectively 93% and 98% of defined samples. 
For some purposes of the analysis, data of the US sample and the pool of the three Serbian samples of the Seven 
Countries Study were also used, as described later. Details on the Seven Countries Study can be found elsewhere25.
Six risk factors used for this analysis were: a) age in years, approximated to the nearest birthday; b) body 
mass index in kg/m2, derived from the measurement of height and weight following the technique described in 
the WHO Manual Cardiovascular Survey Methods26 (WHO Manual); c) smoking habits, derived from a ques-
tionnaire, classified in three variables as never smokers, ex-smokers and smokers treated as dummy variables 
(0–1), with never smokers used as reference in the multivariable models; d) systolic blood pressure in mm Hg, 
measured following the technique of the WHO Manual26, in supine position, with mercury sphygmomanometer: 
two consecutive measurements were averaged and used for analysis; e) heart rate in beats/min, derived from a 
resting ECG tracing; f) serum cholesterol in mmol/L, measured on casual blood samples following the technique 
of Anderson and Keys27.
All methods were carried out in accordance with relevant guidelines and regulations at the time of the field 
examinations, performed in the late 50′ to early 60′. In particular, since baseline data were collected before the era 
of the Helsinki Declaration (June 1964), with consent implied by participation in the examinations, there were 
no expressed approvals from institutional or licensing committees. However, there were subsequently verbal or 
written consents given by all informed participants to collect follow-up data.
Mortality data were collected systematically including the availability of deaths certificates plus other informa-
tion derived from clinical records, interviews with family and hospital physicians, and relatives of the deceased, and 
any other witness of the fatal event. Coding was made by a single reviewer, following defined rules and criteria and 
employing the 8th Revision of the WHO ICD28. In case of multiple causes of death (present in about half of cases) 
and of uncertainties about the principal cause of death, a rank order was adopted with violence, cancer, CHD, stroke 
and other in sequence. CHD was defined by ICD codes 410–413 and cases of sudden death when other specific 
causes could be reasonably excluded. Cases described as chronic CHD or hypertensive heart disease and cases man-
ifested only as heart failure, arrhythmia or blocks were not coded as CHD for reasons given elsewhere29.
Despite the availability of 50-year follow-up data, this analysis was confined to the first 25 years since usually 
predictive tools of CHD events do not consider too long follow-up periods. Subjects carrying a CHD at baseline 
were excluded from analysis, as well as those with missing risk factor measurements, thus reducing the denomi-
nators to 2360 in NE and 2789 in SE.
Cox proportional hazards models were computed separately for NE and SE using the six risk factors as pre-
dictors and 25-year CHD deaths as end-point. Calibration of the models were made using the procedure of 
Greenwood-Nam-D’Agostino as modified by Demler24 (GNDD) that produces chi-squared statistics using 10 
deciles of observed and expected (estimated) risk. This approach represents a sophisticated procedure to be used 
when the material includes survival data and corresponds to the Hosmer-Lemeshaw chi-squared employed for 
the multiple logistic equation that deals only with binary data. Instead of the number of events, the GNDD test 
uses survival probabilities of observed and predicted events.
Calibration was performed on the original models (called SELF) separately for NE and SE, by comparing 
observed and expected risk in decile classes of risk, tested with the GNDD procedure (SELF model). A simulation 
of re-calibration was carried out for the NE group (validation population) applying the SE (derivation population) 
risk function components in five different ways, producing five different re-calibrated models: the same was done 
applying the NE risk function to the SE data. The five re-calibrated models were as follows:
 (1) model SCM applying the whole SE risk function, including (S) (baseline cumulative survival, S(0)), C (coef-
ficients) and M (mean of risk factor levels);
 (2) model CM substituting only C (coefficients) and M (mean of risk factor levels) of the opposite group;
 (3) model C, substituting only C (coefficients);
 (4) model WC, substituting in both areas the original coefficients with another set of coefficients choosing 
the largest ones -for each risk factor- among those available in the original SE and NE models and in 
models derived from other cohorts of the Seven Countries Study using the same baseline risk factors, the 
same end-points and the same length of follow-up; the cohorts were the US Railroad cohort (N = 2406, 
cases = 373, rate 154 per 1000) and the pool of the three Serbian cohorts of Velika Krsna, Zrenjanin and 
Belgrade (N = 1540, cases = 133, rate 86 per 1000); the so-called widest coefficients (WC) were not signifi-
cantly different from those of the original models of both SE and NE groups;
 (5) ALTS model (altered S(0)) computing the chi-squared of the GNDD test after having made artificial (vol-
untary subjective but very small) changes of the original S(0) of the two population groups; a small increase 
was considered for NE (from 0.7698 to 0.8098), and a small decrease for SE (from 0.9354 to 0.9254).
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The risk probabilities predicted by the models in decile classes of risk were computed and used for the final 
estimate of the GNDD chi-squared. The above procedures represent an extreme not previously tested and special 
case (since practically unique) of re-calibration where the parameters of both derivation and validation popula-
tions are fully known.
Results
Table 1 reports mean levels of risk factors, and numbers and rates of CHD fatal events. Risk factor levels of systolic 
blood pressure, serum cholesterol, and smoking habits were significantly higher in NE than in SE, while BMI was 
so in SE versus NE, and no significant difference was found for age and heart rate (although the latter close to 
significance). Death rate from CHD in 25 years was roughly three-fold higher in NE than in SE.
Cox models for the two groups (Table 2) showed that BMI had not significant coefficient in NE, but significant 
in SE, while heart rate and ex-smokers had not significant coefficients in both groups. Age, systolic blood pres-
sure, smokers and serum cholesterol had significant coefficients in both groups. The comparison between the two 
areas showed a large difference in the baseline cumulative survival that contrasted with the absence of significant 
differences of risk factors coefficients.
An intermediate finding of the GNDD procedure is represented by the estimates of risk probabilities for 
observed and predicted (estimated) events in decile classes of risk. A selection of these data (Table 3) indicated 
that the NE re-calibrated risk probabilities were similar to the original ones (SELF), only in the model that substi-
tuted C alone, and the same was the case for SE. Again, in NE models SCM and CM produced gross under- and 
over-estimates of risk, respectively, while the reverse was the true for SE. Also the WC and the ALTS models were 
miss-calibrated.
In Table 3 the final outcome of calibration and re-calibration tests are expressed as p of chi-squared according 
to the procedure of GNDD. In both areas, calibration based on the original (SELF) model was good since associ-
ated with high p value of the chi squared. The same happened when only the coefficient of the opposite population 
were applied, while in all other cases under- or over-estimation or risk were the outcome.
Findings of the above analyses are summarized graphically in Fig. 1 where the SCM model determined an 
under-estimation of risk in NE and an over-estimation of risk in SE. In the case of model CM an over-estimation 
was seen in NE and an under-estimation in SE. These effects were mainly due to the fact that the magnitude of 
NE SE
P of difference (<)Mean and (SD) Mean and (SD)
Age, years 49.3 (5.54) 49.14 (5.31) 0.2619
Body mass index, kg/m2 23.8 (3.05) 24.0 (3.67) 0.0001
Systolic blood pressure, mm Hg 143.7 (20.08) 140.3 (20.97) 0.0001
Heart rate, beats/min 69.1 (13.07) 68.4 (13.10) 0.0632
Serum cholesterol, mmol/L 6.5 (1.32) 5.25 (1.09 0.0001
Never smokers, proportion (*) 15.3 (0.74) 25.0 (0.82) 0.0001
Ex-smokers, proportion (*) 18.0 (0.79) 14.3 (0.66) 0.0001
Smokers, proportion (*) 66.7 (0.97) 60.7 (0.93) 0.0001
CHD fatal CHD in 25 years, N 465 165 —
CHD fatal events, per 1000 in 25 years 197 59 0.0001
Table 1. Mean levels of risk factors and CHD mortality in Northern and Southern Europe. NE = Northern 
Europe; SE = Southern Europe SD = standard deviation (*) for proportion = % and (standard error).
Delta for 
Hazard Ratios
NE SE
P of difference between 
coefficients (*)
Hazard Ratios 
and (95% CI)
Hazard Ratio 
and (95% CI)
Age, years 5 1.36 (1.25–1.49) 1.35 (1.15–1.57) 0.8929
Body mass index, kg/m2 3 1.01 (0.92–1.11) 1.14 (1.00–1.29) 0.1200
Systolic blood pressure, mmHg 20 1.39 (1.28–1.52) 1.42 (1.22–1.65) 0.8549
Heart rate, beats/min 13 1.02 (0.93–1.12) 1.14 (0.99–1.32) 0.2014
Serum cholesterol, mmol/L 1 1.23 (1.15–1.31) 1.25 (1.10–1.43) 0.8051
Never smokers, proportion reference — — —
Ex-smokers, proportion 1 1.15 (0.83–1.61) 1.31 (0.75–2.26) 0.7042
Smokers, proportion 1 1.52 (1.16–2.00) 2.02 (1.35–3.02) 0.2570
S(0) = baseline cumulative survival — 0.7698 0.9354
Table 2. Cox proportional hazards models predicting 25-year CHD mortality as a function of 6 risk factors 
in Northern and Southern Europe. NE = Northern Europe; SE = Southern Europe CI = confidence intervals 
Deltas for Hazard Ratios (HR) roughly correspond to 1 standard deviation of each risk factor. (*) Coefficients 
not reported.
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coefficients in SE was slightly larger than in NE, despite the absence of significant differences between the pairs 
of coefficients. On the other hand, a good estimation of risk was seen for the SELF (original) model and model C. 
Finally, the two models with wide coefficients (WC), and altered S(0) (ALTS) were also miss-calibrated.
Discussion
Strengths and limitations. There was no need to produce a re-calibration in these two population groups 
since for both of them all the data and parameters of the predictive models were fully known, including risk fac-
tor levels, identification of events, cumulative survival and multivariable coefficients of the six risk factors. The 
exercise was directed to apply, in different ways, the parameters of the predictive model of one population to the 
other (and vice-versa) with the purpose to compare the outcome of the simulated re-calibration with the real data. 
The main conclusion was that a good re-calibration could be obtained only when we substituted the risk factor 
coefficients since they were similar in magnitude and not significantly different between the two populations. In 
all other cases, a good re-calibration could not be obtained.
This exercise has several strength points since the two population groups were studied by the same team within 
the same cooperative study, examining population samples of the same sex and age range and in the same years, 
using the same risk factor measurement techniques, the same collection of data procedure, the same follow-up dura-
tion, the same diagnostic criteria for end-points and the same coding rules. By contrast, the two population groups 
Model Details
Estimated risk probabilities
NE SE
Calibrated SELF
Mean observed 0.2519 0.0801
Mean expected 0.2555 0.0829
Decile 1 0.0939 0.0198
Decile 10 0.5532 0.2452
Ratio decile10/decile1 5.89 12.39
p of chi squared of GNDD test 0.7296 0.5942
Re-calibrated SCM
Mean expected 0.1148 0.1908
Decile 1 0.0311 0.0652
Decile 10 0.3107 0.4420
Ratio decile10/decile1 10.0 6.78
p of chi squared of GNDD test <0.0001 <0.0001
Re-calibrated CM
Mean expected 0.3516 0.0547
Decile 1 0.1161 0.0171
Decile 10 0.3516 0.1419
Ratio decile10/decile1 6.40 8.32
p of chi squared of GNDD test <0.0001 <0.0001
Re-calibrated C
Mean expected 0.2624 0.0768
Decile 1 0.0802 0.0243
Decile 10 0.6070 0.1957
Ratio decile10/decile1 7.60 8.06
p of chi squared of GNDD test 0.2820 0.3776
Re-calibrated WC
Mean expected 0.2763 0.0938
Decile 1 0.0628 0.0150
Decile 10 0.7129 0.3295
Ratio decile10/decile1 11.34 21.94
p of chi squared of GNDD test <0.0001 0.0178
Re-calibrated ALTS
Mean expected 0.2141 0.0950
Decile 1 0.0765 0.0229
Decile 10 0.4803 0.2774
Ratio decile10/decile1 4.32 12.09
p of chi squared of GNDD test 0.0265 0.0072
Table 3. Estimated probabilities of CHD mortality risk in deciles of estimated risk from six different models in 
Northern and Southern Europe. (1 calibration, 5 re-calibration). NE = Northern Europe; SE = Southern Europe; 
SELF = original model, respectively NE or SE; SCM = substituting S(0), coefficients and means of risk factors; 
CM = model substituting coefficients and means of risk factors; C = model substituting coefficients only; 
WC = model substituting coefficients with the widest coefficients that had the corresponding HR (95% CI): 
age 1.50 (1.28 1.77); BMI 1.21 (1.05 1.41); systolic blood pressure 1.55 (1.32 1.82); heart rate 1.05 (0.81 1.36); 
cholesterol 1.28 (1.18 1.39); ex-smokers 1.31 (0.75 2.26); smoker 2.18 (1.45 3.28); finally ALTS = substituting 
S(0) with altered S(0): for NE 0.9098 instead of 0.7698; for SE: 0.9254 instead of 0.9354. GNDD = Greenwood-
Nam-D’Agostino-Demler goodness of fit test for re-calibrated survival models: by this test significant difference 
(outlined here in bold) means that re-calibration is not good enough24.
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had different levels of some major risk factor such as blood pressure, serum cholesterol and smoking habits risk, 
different rates of CHD mortality, but eventually similar (and not significantly different) multivariable coefficients 
of risk factors. Moreover, the analysis took advantage from the use of the most recent and sophisticated procedure 
for estimation of calibration and re-calibration24 that takes into proper account the presence of survival data, a 
technique that was not at hand of previous Investigators during the years 2001–2015 when they claimed in different 
datasets that re-calibration is possible without specific reserves11–23. The only common outcome to all models was 
an increasing estimated risk from decile 1 to decile 10 which says that the estimate of relative risk could be relatively 
good, although usually smaller than that provided by the “SELF” (original) models as seen here.
It should be made clear that the SCM model was not the outcome of a real re-calibration but simply a test 
to explore what happened with a re-calibration procedure. Moreover, it was not granted that by applying the 
coefficients of the opposite population produced a good re-calibration. This probably happened only because the 
coefficients of the two populations were very similar. In fact, when we applied the co-called Widest coefficients, 
based on an arbitrary choice (derived however from data of the same study) the re-calibration was not success-
ful, although the coefficients were not significantly different from the original ones. Similarly, the use of slightly 
different baseline cumulative survival was an arbitrary selection showing however that by little variations of S(0) 
outcome might be largely influenced.
There are several limitations in this analysis. In fact, it deals only with male sex and with a restricted age range 
at entry examination. The analysis was limited to few risk factors and to a limited group of population samples, 
with findings that cannot be automatically extrapolated to other situations. Moreover, it can be argued that our 
conclusions cannot be transferred to the present days since population risk factor levels are likely different from 
those of 50 years ago, also due to the more common drug treatment of high blood pressure and high cholesterol 
levels. However, this is not demonstrated and if the levels attained by drug treatment have a predictive value, we 
should not necessarily negate a possible general rule of the relationship between risk factors and CHD events. In 
fact, it is possible that the slope of the relationship should not depend from risk factors distribution.
On the basis of this experience, we feel that the re-calibration process should be carried with much caution owing 
to a number of uncertainties that include the relationship of population sample risk factors with the events collected 
from other sources and the magnitude of the risk factor coefficients coming from other population experiences. This 
is enough to praise for an overall need of re-evaluation of most investigations11–23 that, without a proper technique 
for statistically assessing the potential differences24, concluded that re-calibration is a fair method and might there-
fore be used, with no specific caution. In general it appears that in order to have a good re-calibration one needs: A) 
a very good (and/or very lucky) estimate of baseline cumulative survival S(0) that is probably hard to obtain since 
usually derived from external data; indeed, the estimate of the baseline cumulative survival, usually derived from 
sparse and diverse sources, cannot be fully trusted to reflect the reality of the study population; B) a set of “imported” 
coefficients not significantly different from the theoretical (and unknown) ones, but also very similar in magnitude.
Contributions from the literature. Most of the re-calibration procedures found in the literature11–23 
started from the assumption that the “imported” coefficients were valid and similar or not significantly different 
Figure 1. Kaplan-Meier observed versus expected CHD mortality probabilities in Northern (left: NE) versus 
Southern (right: SE) Europe in comparison to the identity lines and depending on whether calibration and re-
calibration (by five different methods) curves were performed using models: a) with self data (SELF: either NE or SE), 
corresponding to proper calibration; or re-calibrating by substituting: b1) S(0), coefficients and means of risk factors 
(SCM); b2) coefficients and means of risk factors (CM); b3) coefficients only (C); b4) deliberately altered S(0) (ALTS); 
and b5) the widest coefficients (WC) derived from  four population groups of the same study for the six risk factors.
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from those (unknown) of the “importing” (validation) populations. These studies were carried in 13 different 
countries (9 European and two Asian countries, plus Australia and the USA). Several contributions have put 
together three components derived from largely different sources: risk factor distribution from population sam-
ples, mortality data from regional or national origin (not related to a real follow-up) and coefficients from the 
Euro-Score project or the Framingham Heart Study14,15,17–21. Only three studies11,12,22 have reported the risk func-
tion of the “validation population”, while others did not do so although it was clear that it could have been com-
puted and presented13,16,19,20,23. This was particularly unfortunate since a good occasion was lost to investigate the 
problem of the possible homogeneity of risk factor coefficients. Some contributions have openly claimed that 
the possible heterogeneity of multivariable coefficients was not a problem, quoting references that did not fully 
support this concept13,18. However, when both the high and low risk functions of the Euro-Score project were 
tested, the high-risk model did not produce good calibration13,16,20,21. This may depend upon a casual combination 
of high levels of risk factor coefficients and high levels of estimated survival that may tend to balance one each 
other. In fact, in a test made on our NE population group we found that applying the widest coefficients (that by 
themselves induce a poor calibration) together with higher levels of survival (that by themselves induce a poor 
calibration) ended up in an acceptable calibration.
In at least three contributions the Hosmer-Lemeshaw chi-squared test was applied to data derived from mod-
els that included survival data19,21,23, that is in an improper way.
Conclusions. On the basis of this experience, good re-calibration can be achieved only in a few cases and 
when lucky circumstances do coincide. Therefore, much caution must be used in reaching valid conclusions.
The re-calibration procedure will probably lose its role when more and more countries will be able to produce 
their own risk functions. However, this process may stimulate the need to study deeper the problem of the heter-
ogeneity or non-heterogeneity of multivariable coefficients of risk factors. The absence of systematic differences 
across multivariable coefficients of CHD risk function has been repeatedly shown comparing the cohorts and/or 
areas of the Seven Countries Study3,29–34 but this seems to be an isolated effort that calls for a systematic approach 
from many different sources. There is a theoretical, and not only practical issue, since demonstrating the overall 
similarity in the magnitude of multivariable coefficients could represent the possible identification of a general 
biological rule linking risk factor levels and events, when everything else being equal.
This analysis was mainly a methodological exercise, but we acknowledge the fact that a number of “new risk 
factors” may improve the prediction of coronary events. Among others, one may wish to explore the effects 
of statins on cardiovascular outcomes by smoking status35, vitamin-D deficiency and non-lipid biomarkers of 
cardiovascular risk36, evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular dis-
eases37, association of serum lipids and CHD in just observational studies38 and whether low high-density 
lipoprotein-cholesterol should be treated39. Unfortunately, all these terms either were not available in our old 
study or the questions were far from our main objective.
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